Chronic fatigue syndrome: Intracellular immune deregulations as a possible etiology for abnormal exercise response

Medical Hypotheses

Volumn 62, Issue 5, 2004, Pages 759-765

  Nijs, Jo ^a,b,g   De Meirleir, Kenny ^a   Meeus, Mira ^a   McGregor, Neil R ^c,d   Englebienne, Patrick ^e,f  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b Hogeschool Antwerpen   (Belgium)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f R E D LABORATORIES   (Belgium)

^g AZ VUB KRO Gebouw Niveau 1   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; RIBONUCLEASE; SYNTHETASE;

BLOOD FLOW; CHRONIC FATIGUE SYNDROME; DEREGULATION; ENZYME ACTIVATION; EXERCISE; HUMAN; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOREGULATION; MUSCLE WEAKNESS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SKELETAL MUSCLE; VASODILATATION;

EID: 1942500229     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.030     Document Type: Article

References (72)

1. Fukuda K, Strauss SE, Hickie I, et al. The Chronic Fatigue Syndrome, a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959s.
2. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic Fatigue Syndrome: a working case definition. Ann Intern Med 1988;108:387-9.
3. Evengard B, Schacterle RS, Komaroff AL. Chronic Fatigue Syndrome: new insights and old ignorances. J Intern Med 1999;246:455-69.
4. McCully KK, Sisto SA, Natelson BH. Use of exercise for treatment of chronic fatigue syndrome. Sports Med 1996;21:35-48.
5. van Middendorp H, Geenen R, Kuis W, Heijnen CJ, Sinnema G. Psychological adjustment of adolescent girls with chronic fatigue syndrome. Pediatrics 2001;107:1-8.
6. De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Exercise capacity in chronic fatigue syndrome. Arch Intern Med 2000;160:3270-7.
7. Fishier B, Dendale P, Michiels V, Cluydts R, Kaufman L, De Meirleir K. Physical fatigability and exercise capacity in chronic fatigue syndrome: association with disability, somatization and psychopathology. J Psychosom Res 1997;42:369-78.
8. Riley MS, O'Brien CJ, McCluskey DR, Bell NP, Nicholls DP. Aerobic work capacity in patients with chronic fatigue syndrome. Brit Med J 1990;301:953-6.
9. Sisto SA, LaManca J, Cordero DL, Bergen MT, Ellis SP, Drastal S, et al. Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome. Am J Med 1996;100:634-40.
10. Fulcher KY, White PD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. J Neurol Neurosurg Neuropsych 2000;69:302-7.
11. 31P nuclear magnetic resonance spectroscopy. Chest 1992;102:1716-22.
12. Sargent C, Scroop GC, Nemeth PM, Burnet RB, Buckley JD. Maximal oxygen uptake and lactate metabolism are normal in chronic fatigue syndrome. Med Sci Sports Exerc 2002;34:51-6.
13. Rowbottom D, Keast D, Pervan Z, Morton A. The physiological response to exercise in chronic fatigue syndrome. J Chronic Fatigue Syndr 1998;4:33-49.
14. Kent-Braun JA, Sharma KR, Weiner MW, Massie B, Miller RG. Central basis of muscle fatigue in chronic fatigue syndrome. Neurology 1993;43:125-31.
15. Nijs J, De Meirleir K, Wolfs S, Duquet W. Disability evaluation in chronic fatigue syndrome: associations between exercise capacity and activity limitations/participation restrictions. Clin Rehabil 2004;18:109-18.
16. Sorensen B, Streib JE, Strand M, Make B, Giclas PC, Fleshner M, et al. Complement activation in a model of chronic fatigue syndrome. J Allergy Clin Immunol 2003;112:397-403.
17. Snell CR, Vanness JM, Strayer DR, Stevens SR. Physical performance and prediction of 2-5A Synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo 2002;16:107-10.
18. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/Rnase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18:596-5104.
19. Suhadolnik RJ, Peterson DL, Cheney PR, et al. Biochemical deregulation of the 2-5A synthetase/Rnase L antiviral defense pathway in chronic fatigue syndrome. J Chronic Fatigue Syndr 1999;5:223-42.
20. De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for Chronic Fatigue Syndrome. Am J Med 2000;108:99-105.
21. Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997;17:377-85.
22. Bisbal C, Martinand C, Silhol M, Lebleu B, Salehzada T. Cloning and characterization of a RNase L inhibitor. J Biol Chem 1995;270:13308-17.
23. Martinand C, Montavon C, Salehzada T, Silhol M, Lebleu B, Bisbal C. RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/Rnase L pathway in human T Cells. J Virol 1999;73:290-6.
24. Demettre E, Bastide L, D'Haese A, et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 2002;277:35746-51.
25. Bennett V, Otto E, Kunimoto M, et al. Diversity of ankyrins in the brain. Biochem Soc Trans 1991;19:1034-9.
26. Englebienne P, Herst CV, De Smet K, D'Haes A, De Meirleir K. Interactions between RNase L ankyrin-like domain and ABC transporters as a possible origin for pain, ion transport, CNS and immune disorders of Chronic Fatigue Immune Dysfunction Syndrome. J Chronic Fatigue Syndr 2001;8:83-102.
27. Nijs J, Demanet C, McGregor N, De Becker P, Verhas P, Englebienne P, et al. Monitoring a hypothetical channelopathy in chronic fatigue syndrome: preliminary observations. J Chronic Fatigue Syndr 2003;11:117-33.
28. Bisbal C, Silhol M, Laubenthal H, et al. The 2′-5′ oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol 2000;20:4959-69.
29. Englebienne P. RNase L in health and disease - What did we learn recently? J Chronic Fatigue Syndr 2003;11(2):97-109.
30. De Becker P, McGregor N, De Meirleir K. A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome. J Intern Med 2001;250:234-40.
31. Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome. Eur J Clin Microbiol Infect Dis 1999;18:859-65.
32. Vojdani A, Choppa PC, Tagle C, Andrin R, Samini B, Lapp CW. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic fatigue Syndrome. FEMS Immunol Med Microbiol 1998;22:355-65.
33. Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol 2002;34:209-14.
34. Baseman J, Tully J. Mycoplasmes: sophisticated, reemerging, and burdened by their notority. Emerg Infect Dis 1997;3:21-32.
35. Baum SC. Mycoplasma pneumoniae and atypical pneumonia. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 1713-8.
36. Peterszegi G, Texier S, Robert L. Cell death by overload of the elastin-laminin receptor on human activated lymphocytes: protection by lactose and melibiose. Eur J Clin Invest 1999;29:166-72.
37. Dabbagh K, Laurent GJ, Shock A, Leoni P, Papakrivopoulou J, Chambers RC. Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J Cell Physiol 2001;186:73-81.
38. Nijs J, De Meirleir K, Coomans D, De Becker P, Nicolson GL. Deregulation of the 2,5A synthetase RNase L antiviral pathway by Mycoplasmas in subsets of Chronic fatigue Syndrome. J Chronic Fatigue Syndr 2003;11(2):37-50.
39. Englebienne P, Frémont M, Vaeyens F, Herst V, Verhas M, De Becker P, et al. Chronic fatigue syndrome (CFS) and multiple sclerosis (MS) as subsets of a group of cellular immunity disorders. ME/CFS: the medical practitioners' challenge. In: Proceedings at Sydney International Conference, 2001. p. 35-42.
40. De Meirleir K, De Becker P, Nijs J, Peterson D, Nicolson G, Patarca R, et al. Chronic Fatigue Syndrome etiology, the immune system and infection. In: Englebienne P, De Meirleir K, editors. Chronic Fatigue Syndrome: a biological approach. Boca Raton: CRC Medical Publications; 2002. p. 201-28 [chapter 8].
41. Iordanov MS, Wong J, Bell JC, Magun BE. Activation of NF-κB by double-stranded RNA (dsRNA) in the absence of protein kinase R and RNase L demonstrates the existence of two separate dsRNA-triggered antiviral programs. Mol Cell Biol 2001;21:61-72.
42. Uetani K, Der SD, Zamanian-Daryoush M, de la Motte C, Lieberman BY, Williams BRG, Erzurum SC. Central role of double-stranded RNA-activated protein kinase in microbial induction of nitric oxide synthase. J Immunol 2000;165:988-96.
43. Paludan SR, Ellermann-Eriksen S, Mogensen SC. NF-κB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-γ-induced nitric oxide production in macrophages. J Gen Virol 1998;79:2785-93.
44. Vecchiet J, Cipollone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neuroscience Letters 2003;335:151-4.
45. Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Intern J Neuroscience 2003;113:683-701.
46. Pall ML, Satterle JD. Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder. Ann NY Acad Sci 2001;933:323-9.
47. Casey AK, McDonough P, Finley MR, Behnke BJ, Richardson TE, Marlin DJ, et al. NO inhalation reduces pulmonary arterial pressure but not hemorrhage in maximal exercising horses. J Appl Physiol 2001;91:2674-8.
48. Silverthorn DU, Ober WC, Garrison CW, Silverthorn AC. Blood flow and the control of blood pressure. In: Silverthorn DU, Ober WC, Garrison CW, Silverthorn AC, editors. Human physiology: an integrated approach. New Jersey: Prentice Hall; 2001. p. 445-6 [chapter 15].
49. Halliwill JR, Minson CT, Joyner MJ. Effect of systemic nitric oxide synthase inhibition on postexercise hypotension in humans. J Appl Phsyiol 2000;89:1830-6.
50. Scarim AL, Arnush M, Blair LA, Concepcion J, Heitmeier MR, Scheuner D, et al. Mechanisms of β-cell death in response to double-stranded (ds) RNA and interferon-γ. Am J Pathol 2001;159:273-83.
51. Fulle S, Belia S, Vecchiet J, Morabito C, Vecchiet L, Fano G. Modification of the functional capacity of sarcoplasmic reticulum membranes in patients suffering from chronic fatigue syndrome. Neuromusc Dis 2003;13:479-84.
52. Piec G, Mirkovitch J, Palacio S, et al. Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro. Infect Immun 1999;67:6281-5.
53. Rawadi G. Mycoplasma fermentans interaction with monocytes/macrophages: molecular basis. Microbes Infect 2000;2:955-64.
54. Takeuchi O, Kaufmann A, Grote K, et al. Cutting edge: preferentially the R-stereoisomer of the Mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signalling pathway. J Immunol 2000;164:554-7.
55. Rawadi G, Garcia J, Lemercier B, Roman-Roman S. Signal transduction pathways involved in the activation of NF-κB, AP-1, and c-fos by Mycoplasma fermentans membrane lipoproteins in macrophages. J Immunol 1999;162:2193-203.
56. Feng S-H, Tsai S, Rodriguez J, Lo S-C. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol 1999;19:7995-8002.
57. Garcia J, Lemercier B, Roman-Roman S, Rawadi G. A Mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-κB activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways. J Biol Chem 1998;273:34391-8.
58. Feng S-H, Lo S-C. Lipid extract of Mycoplasma penetrans proteinase K-digested lipid-associated membrane proteins rapidly activates NF-κB and activator protein 1. Infect Immun 1999;67:2951-6.
59. Kikkawa S, Matsumoto M, Sasaki T, Nishiguchi M, Tanaka K, Toyoshima K, et al. Complement activation in Mycoplasma fermentans-induced Mycoplasma clearance from infected cells: probing of the organism with monoclonal antibodies against M161Ag. Infect Immun 2000;68:1672-80.
60. Chia JKS, Chia LY. Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis 1999;29:452-3.
61. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 2003;111:557-66.
62. Levine S. Prevalence in the cerebrospinal fluid of the following infectious agents in a cohort of 12 CFS subjects: Human Herpes Virus-6 and 8; Chlamydia species; Mycoplasma species; EBV; CMV; and Coxsackievirus. J Chronic Fatigue Syndr 2001;9:41-51.
63. Fischer SF, Schwarz C, Vier J, Häcker G. Characterization of antiapoptotic activities of Chlamydia pneumoniae in human cells. Infect Immun 2001;69:7121-9.
64. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, et al. Chlmaydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression. Circulation 1999;100:1369-73.
65. Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH. Chlamydia pneumoniae activates nuclear factor κB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res 2000;90:76-81.
66. Molestina RE, Miller RD, Lentsch AB, Ramirez JA, Summersgill JT. Requirement for NF-κB in transcriptional activation of monocyte chemotactic protein 1 by Chlmaydia pneumoniae in human endothelial cells. Infect Immun 2000;68:4282-8.
67. Wahl C, Oswald F, Simnacher U, Weiss S, Marre R, Essig A. Survival of Chlmaydia pneumoniae-infected mono mac 6 cells is dependent on NF-κB binding activity. Infect Immun 2001;69:7039-45.
68. Zaragoza C, Ocampo CJ, Saura M, McMillan A, Lowenstein CJ. Nitric oxide inhibition of coxsackievirus replication in vitro. J Clin Invest 1997;100:1760-7.
69. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994;79:1137-46.
70. Bell EJ, McCartney RA, Riding MH. Coxsackie B viruses and myalgic encephalomyeltitis. J R Soc Med 1988;81:329-31.
71. Yousef GE, Bell EJ, Mann GF, Murugesan V, Smith DG, McCartney RA. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1988;1:146-50.
72. Levy J. Viral studies of chronic fatigue syndrome, introduction. Clin Infect Dis 1994;18(suppl 1):S117.